Search Results
Your search for David M. Gershenson, MD matches 5 pages
Showing 1 - 5Trametinib Improves Progression-Free Survival vs Standard-of-Care Treatment in Recurrent Low-Grade Serous Ovarian Carcinoma
As reported in The Lancet by David M. Gershenson, MD, of the Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, and colleagues, the phase II/III GOG 281/LOGS trial showed that trametinib improved progression-free survival vs standard-of-care treatment...
GOG 281/LOGS: Trametinib vs Standard of Care in Recurrent Low-Grade Serous Ovarian Carcinoma
In a phase II/III trial reported in The Lancet, David M. Gershenson, MD, and colleagues found that trametinib improved progression-free survival vs standard of care treatment in women with low-grade serous ovarian carcinoma. As stated by the investigators, “Low-grade serous carcinoma of the ovary...
Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum
In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...
What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Ever since the landmark studies of Griffiths and colleagues in the 1970s,1 primary cytoreductive surgery followed by chemotherapy with the objective of achieving minimal residual disease has been the standard approach for women with advanced-stage epithelial ovarian cancer. However, what is...
Ovarian Cancer Trialists Forming Work Group to Standardize Definition of Pathologic Complete Response
Ovarian cancer clinical trialists are forming a working group to develop a standard definition of pathologic complete response in ovarian cancer treated with neoadjuvant chemotherapy. Such agreement within the field potentially would enable the U.S. Food and Drug Administration (FDA) to consider...
